| Literature DB >> 29471831 |
Antoni Llueca1,2,3, Anna Serra4, Isabel Rivadulla5,4, Luis Gomez5,4, Javier Escrig5,4,6.
Abstract
BACKGROUND: The peritoneal carcinomatosis index (PCI) can be used to quantify the tumor burden in patients with advanced ovarian cancer. The aim of the present study was to establish a predictive model for suboptimal cytoreductive surgery (SCS) (residual tumor of > 1 cm) using preoperative and intraoperative determination of the PCI.Entities:
Keywords: Advanced ovarian cancer; Cytoreductive surgery; Peritoneal carcinomatosis index
Mesh:
Year: 2018 PMID: 29471831 PMCID: PMC5824576 DOI: 10.1186/s12957-018-1339-0
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Radiologic-laparoscopic criteria for unresectability
| CT scan | Lung metastasis |
| Diagnostic laparoscopy | Diffuse serous small bowel disease |
CT computed tomography, NACT neoadjuvant chemotherapy
Clinicopathologic characteristics of all patients
| Characteristics | Nr. | (%) |
|---|---|---|
| All cases | 80 | |
| Age, median (range), years | 59 (30–84) | |
| FIGO stage | ||
| III c | 55 | 69 |
| IV | 25 | 31 |
| Ascites | ||
| Yes | 22 | 27.5 |
| No | 58 | 72.5 |
| Histology | ||
| Serous | 44 | 55 |
| Endometrioid/clear cells | 12 | 15 |
| Mucinous | 8 | 10 |
| Other adenocarcinoma | 16 | 20 |
| PCI, median (range) | 12 (2–35) | |
| PCI 1–10 | 34 | 42.5 |
| PCI 11–20 | 25 | 31.2 |
| PCI > 20 | 21 | 26.2 |
| Duration of surgery, median (range) | 360 (60–638) | |
| Residual tumor | ||
| CCS | 64 | 80 |
| OCS | 5 | 6.2 |
| SCS | 11 | 13.8 |
PCI peritoneal carcinomatosis index, CCS complete cytoreductive surgery, OCS optimal cytoreductive surgery, SCS suboptimal cytoreductive surgery
Diagnostic parameters for SCS by technique
| SEN (95% CI) | SPC (95% CI) | PPVa (95% CI) | NPVa (95% CI) | |
|---|---|---|---|---|
| CT scan | 27% (6–61) | 91% (82–97) | 33% (8–70) | 89 (79–95) |
| Laparoscopy | 38% (9–76) | 88% (74–96) | 33% (6–73) | 90 (76–97) |
| Laparotomy | 73% (39–94) | 81% (70–90) | 38% (18–62) | 95% (86–99) |
| CT plus laparoscopyb | 38% (14–69) | 98% (87–99) | 75% (27–98) | 91% (82–96) |
SCS suboptimal cytoreductive surgery, 95%CI 95% confidence interval, SEN sensitivity, SPC specificity, PPV positive predictive value, NPV negative predictive value, CT computed tomography
aFor an SCS prevalence of 13.8%
bCriteria for SCS: CT plus laparoscopy positive for SCS if both show a PCI of > 20
Fig. 1CUSUM graph relationship between visceral resections and postoperative complications
Studies using CT to predict surgical outcome
| Study |
| OCS (%) | SEN (%) | SPC (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|
| Nelson | 42 | 69 | 92 | 71 | 67 | 94 |
| Meyer | 28 | 57 | 58 | 100 | 100 | 55 |
| Bristow | 41 | 49 | 100 | 85 | 87 | 100 |
| Dowdy | 87 | 71 | 64 | 81 | 57 | 85 |
| Llueca | 80 | 86 | 91 | 27 | 89 | 33 |
CT computed tomography, OCS optimal cytoreductive surgery, SEN sensitivity, SPC specificity, PPV positive predictive value, NPV negative predictive value
Predictive values depending on prevalence of SCS (CT + laparoscopy)
| SCS: prevalence | SCS: PPV | SCS: NPV |
|---|---|---|
| 10% | 68% (17–98) | 93% (85–98) |
| 20% | 83% (40–99) | 86% (76–93) |
| 30% | 89% (55–99) | 79% (67–88) |
| 40% | 93% (65–99) | 70% (58–81) |
| 50% | 95% (72–99) | 61% (48–73) |
For sensitivity of 38% and specificity of 98%
SCS suboptimal cytoreductive surgery, CT computed tomography, PPV positive predictive value, NPV negative predictive value
Fig. 2MUAPOS guide to manage AOC. MUAPOS Multidisciplinary Unit for Abdominal Pelvic Oncology Surgery, AOC advanced epithelial ovarian cancer, PDS primary debulking surgery, IDS interval debulking surgery, CHT chemotherapy, NACT neoadjuvant chemotherapy, RLCU radiologic-laparoscopic criteria for unresectability